MAR 0 8 2006

WO 03/002567

WO 05/016929

AB

Signature

PTO/SB/08A (08-03)
Approved for use through 7/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE duction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

AstraZeneca AB

AstraZeneca AB

Date Considered 2

Substitute for Form 1449/PTO Complete if Known Application Number Notwot Assisted 2 9/2006 INFORMATION DISCLOSURE Filing Date BASARAB STATEMENT BY APPLICANT First Named Inventor Not Yet Assigned 1624 (Use as many sheets as necessary) Art Unit Not Yet Assigned E. LEESER **Examiner Name** Attorney Docket No. 101171-1P US SHEET 1 of 1 **U.S. PATENT DOCUMENTS** Pages, Columns, Lines, Where **Document Number** Examiner Cite **Publication Date** Name of Patentee or Relevant Passages or Relevant Number - Kind Code² (if known) Initials* MM-DD-YYYY Applicant of Cited Document Figures Appear **FOREIGN PATENT DOCUMENTS** Pages, Columns. Foreign Patent Document Name of Patentee or Lines, Where **Publication Date** Examiner Applicant of Cited Document Relevant Passages Country Code3 - Number4 - Kind Code5 (* known) т Initials' MM-DD-YYYY or Relevant Figures Appear

*EXAMINER: Initial if efference considered; whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

01-03-03

02/24/05

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08B (08-03)

Approved for use through 7/31/2008. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

er the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Substitute for Form 1449/PTO

PAR THANK

(Use as many sheets as necessary)

SHEET 1 of 1

Complete if Known				
Application Number	10/567797			
Filing Date	Not you Assigned 2/9/2006			
First Named Inventor	Morningstur-et-et BASAIRALB			
Art Unit	Not-Yot Accigned 624			
Examiner Name	Not-Yot Assigned E. LEESER			
Attorney Docket No.	101171-1P US			

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		L ₅	
EL	AA	GHORAB, MOUSTAFA M, Synthesis and Radiation Stability of some new biologically active pyrazolo [3,4-d]pyrimidines, 2000, pp. 93-110, National Center for Radiation Research and Technology, Egypt			
Examiner Signature		Jeen !	2/20/200°	7	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

*EXAMINER: Initial if refereace considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.